BCIQ Profiles

Company Profile ReportTarget Profile Report
0702 ECP H Highlightll
BioCentury & Getty Images

Emerging Company Profile

Hangzhou Highlightll: Twice the target, hold the tox

TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases

Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity while keeping toxicity in check to treat a broad range of autoimmune diseases. 

Jul 3, 2021 | 2:04 AM GMT

Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against the same targets to treat a broad range of autoimmune diseases. Both compounds would need to find a foothold in a crowded marketplace.

Hangzhou Highlightll Pharmaceutical Co. Ltd.

Read the full 1044 word article

How to gain access

Continue reading with a
two-week free trial.